FierceBiotech4d
FDA gives Amylyx green light for phase 1 ALS trial after clinical hold
After raising questions surrounding dosing levels, the FDA has freed Amylyx’s early-stage amyotrophic lateral sclerosis (ALS) ...
GlobalData on MSN3d
FDA lifts clinical hold on Amylyx’s Phase I ALS trial
This is the latest venture for Amylyx into the ALS field after its previous therapy Relyvrio was pulled from the market in ...
biopharma-reporter2d
Amylyx Pharmaceuticals gets FDA go ahead for phase 1 ALS trial
The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of ALS ...
BioSpace3d
FDA Presses Pause on Atara’s Programs, Play on Amylyx’s ALS Assets
The FDA is putting Atara’s active Investigational New Drug applications on hold due to manufacturing concerns at a ...
Amylyx Says FDA Lifts Clinical Hold on ALS-Drug Trial
The company in March said its ALS drug Relyvrio had failed a late-stage clinical trial, and the stock has sunk more than 78% over the past year. Amylyx pulled Relyvrio from the market, cut its ...
bovnews2d
Amylyx Pharmaceuticals Inc (AMLX) Stock’s -0.17% Decrease This Year: What’s the Story?
Amylyx Pharmaceuticals Inc (AMLX) stock saw a decline, ending the day at $3.45 which represents a decrease of $-0.15 or -4.17% from the prior close of $3.6. The stock opened at $3.43 and touched a low ...
Morningstar4d
Amylyx Says FDA Lifts Clinical Hold on ALS-Drug Trial
Amylyx Pharmaceuticals said the Food and Drug Administration had lifted its clinical hold on a trial of the company's treatment for patients with ALS. The Cambridge, Mass., company is now working ...
ETF Daily News4d
Barclays PLC Grows Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)
Barclays PLC boosted its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 91.1% during the third quarter, Holdings Channel reports.The firm owned 84,572 shares of ...
Investing4d
FDA clears Amylyx to resume ALS drug trial in North America
CAMBRIDGE, Mass. - Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX), a $245.1 million market cap biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has lifted the ...